Chicago Sun-Times

FDA OKS CHEAPER RIVAL TO EPIPEN ALLERGY SHOT

-

There will be new competitio­n for EpiPen, the emergency allergy medicine that made Mylan, its manufactur­er, a symbol of pharmaceut­ical company greed.

The federal Food and Drug Administra­tion has approved Adamis Pharmaceut­icals Corp.’ s product, called Symjepi, which should go on sale later this year.

Symjepi is a syringe that’s prefilled with the hormone epinephrin­e, which helps stop life- threatenin­g allergic reactions from insect stings and bites, foods such as nuts and eggs and certain medication­s.

The San Diego company says its product is easier to use than Mylan’s EpiPen, a spring- loaded syringe filled with a set dose that comes with a training device.

Symjepi also is smaller than EpiPen, so it’s easier to fit in a pocket or purse. Most children and adults with severe food or insect allergies carry a device wherever they go and leave a spare at home, school or work.

Adamis says it’s still lining up a distributo­r and hasn’t set the exact price for its product, which will be sold in pairs, like EpiPen.

But Adamis spokesman Mark Flather said Symjepi is intended to be a “low- cost alternativ­e” to EpiPen and similar products, and the company is aiming to sell it for less than generic EpiPens.

In a note to investors, Evercore ISI analyst Umer Raffat wrote that Symjepi is not identical to EpiPen, so the price Adamis sets “will obviously be an important considerat­ion.”

Mylan, which has U. S. headquarte­rs near Pittsburgh, launched generic EpiPens last December in an effort to deflect mounting criticism.

EpiPens cost about $ 630 to $ 700 without insurance, while the generic version retails for about $ 225 to $ 425.

Last summer, the company came under fire for repeatedly raising the price of EpiPens, and CEO Heather Bresch was grilled by a Congressio­nal committee.

Mylan hiked the price of a pair of EpiPens from $ 94 in 2007, when the company acquired the product, to $ 608 last year. The devices need to be replaced each year, adding to the financial sting.

Analysts and others have estimated it costs less than $ 20 to produce a pair of EpiPens.

While EpiPen has other rival products, doctors tend to prescribe EpiPen because it’s so well known.

 ?? | ADAMIS PHARMACEUT­ICALS CORP; AP ??
| ADAMIS PHARMACEUT­ICALS CORP; AP
 ??  ?? The company behind the Symjepi syringe ( left), just approved by the FDA, says it will be a “low- cost alternativ­e” to the EpiPen ( above).
The company behind the Symjepi syringe ( left), just approved by the FDA, says it will be a “low- cost alternativ­e” to the EpiPen ( above).

Newspapers in English

Newspapers from United States